Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Journal of Biological Chemistry

Volumn 291, Issue 17, 2016, Pages 9218-9232

  Zhou, Nan ^a,b   Pan, Ting ^a,b   Zhang, Junsong ^a,b   Li, Qianwen ^a,b   Zhang, Xue ^a,b   Bai, Chuan ^a,b   Huang, Feng ^a,b   Peng, Tao ^c   Zhang, Jianhua ^d   Liu, Chao ^a   Tao, Liang ^b   Zhang, Hui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; CYTOLOGY; PEPTIDES; VIRUSES;

COMPARATIVE ANALYSIS; FOOD AND DRUG ADMINISTRATION; GLYCOPEPTIDE ANTIBIOTICS; HIGH THROUGHPUT SCREENING; POTENTIAL INHIBITORS; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS; VIRUS-LIKE PARTICLES;

DISEASES;

AMIODARONE; CATHEPSIN L; CELL RECEPTOR; DALBAVANCIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; TELAVANCIN; VANCOMYCIN; VIRUS FUSION INHIBITOR; ANTIINFECTIVE AGENT; CTSL1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EBOLAVIRUS; ENDOSOME; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; LYSOSOME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; VIRUS ENTRY; VIRUS LIKE AGENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HELA CELL LINE; HEMORRHAGIC FEVER, EBOLA; METABOLISM; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY;

ANTI-BACTERIAL AGENTS; CATHEPSIN L; EBOLAVIRUS; ENDOSOMES; HELA CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LYSOSOMES; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TEICOPLANIN; VIRUS INTERNALIZATION;

EID: 84965017910     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.716100     Document Type: Article

References (52)

1. Kiley, M. P., and Bowen., E. T., Eddy, G. A., Isaäcson, M., Johnson, K. M., and McCormick., J. B., Murphy, F. A., Pattyn, S. R., Peters, D., and Prozesky., O. W., Regnery, R. L., Simpson, D. I., Slenczka, W., Sureau, P., van der Groen, G., et al. (1982) Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology 18, 24-32
2. World Health Organization (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56, 271-293
3. World Health Organization (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull. World Health Organ. 56, 247-270
4. Jahrling, P. B., and Geisbert., T. W., Dalgard, D. W., Johnson, E. D., and Ksiazek., T. G., Hall, W. C., and Peters, C. J. (1990) Preliminary report: isolation of Ebola virus from monkeys imported to U.S.A. Lancet 335, 502-505
5. Le Guenno, B., Formenty, P., Formentry P, Wyers, M., Gounon, P., Walker, F., and Boesch, C. (1995) Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345, 1271-1274
6. Towner, J. S., and Sealy., T. K., Khristova, M. L., Albariño, C. G., Conlan, S., and Reeder., S. A., Quan, P. L., Lipkin, W. I., Downing, R., and Tappero., J. W., Okware, S., Lutwama, J., Bakamutumaho, B., Kayiwa, J., Comer, J. A., et al. (2008) Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4, e1000212
7. Alvarez, C. P., Lasala, F., Carrillo, J., Muñiz, O., Corbí, A. L., and Delgado, R. (2002) C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 6841-6844
8. Chan, S. Y., and Empig., C. J., Welte, F. J., Speck, R. F., Schmaljohn, A., and Kreisberg., J. F., and Goldsmith, M. A. (2001) Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106, 117-126
9. Gramberg, T., Hofmann, H., Möller, P., Lalor, P. F., Marzi, A., Geier, M., Krumbiegel, M., Winkler, T., Kirchhoff, F., Adams, D. H., Becker, S., Münch, J., and Pöhlmann, S. (2005) LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 340, 224-236
10. Kondratowicz, A. S., and Lennemann., N. J., Sinn, P. L., Davey, R. A., and Hunt., C. L., Moller-Tank, S., Meyerholz, D. K., Rennert, P., and Mullins., R. F., Brindley, M., Sandersfeld, L. M., Quinn, K., Weller, M., McCray, P. B., Jr., Chiorini, J., and Maury, W. (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl. Acad. Sci. U.S.A. 108, 8426-8431
11. O'Hearn, A., Wang, M., Cheng, H., Lear-Rooney, C. M., Koning, K., Rumschlag-Booms, E., Varhegyi, E., Olinger, G., and Rong, L. (2015) Role of EXT1 and glycosaminoglycans in the early stage of filovirus entry. J. Virol. 89, 5441-5449
12. Shimojima, M., Takada, A., Ebihara, H., Neumann, G., Fujioka, K., Irimura, T., Jones, S., Feldmann, H., and Kawaoka, Y. (2006) Tyro 3 family mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109-10116
13. Takada, A., Watanabe, S., Ito, H., Okazaki, K., Kida, H., and Kawaoka, Y. (2000) Downregulation ofβ1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278, 20-26
14. Saeed, M. F., and Kolokoltsov., A. A., Albrecht, T., and Davey, R. A. (2010) Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoSPathog. 6, e1001110
15. Nanbo, A., Imai, M., Watanabe, S., Noda, T., Takahashi, K., Neumann, G., Halfmann, P., and Kawaoka, Y. (2010) Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoSPathog. 6, e1001121
16. Carette, J. E., Raaben, M., Wong, A. C., and Herbert., A. S., Obernosterer, G., Mulherkar, N, and Kuehne., A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., Dal Cin, P., Dye, J. M., and Whelan., S. P., Chandran, K., and Brummelkamp, T. R. (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343
17. Chandran, K., and Sullivan., N. J., Felbor, U., Whelan, S. P., and Cunningham, J. M. (2005) Endosomal proteolysis of the Ebolavirus glycoprotein is necessary for infection. Science 308, 1643-1645
18. Mingo, R. M., and Simmons., J. A., Shoemaker, C. J., Nelson, E. A., and Schornberg., K. L., D'Souza, R. S., Casanova, J. E., and White, J. M. (2015) Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1 + endolysosomes is a rate-defining step. J. Virol. 89, 2931-2943
19. Rampling, T., Ewer, K., Bowyer, G., Wright, D., and Imoukhuede., E. B., Payne, R., Hartnell, F., Gibani, M., Bliss, C, Minhinnick, A., Wilkie, M., Venkatraman, N, Poulton, I., Lella, N, Roberts, R., et al. (2015) A monovalent chimpanzee adenovirus Ebola vaccine-preliminary report. N Engl. J. Med. 10.1056/NEJMoa1411627
20. Regules, J. A., and Beigel., J. H., Paolino, K. M., Voell, J., Castellano, A. R., Munoz, P., and Moon., J. E., Ruck, R. C, Bennett, J. W., and Twomey., P. S., Gutierrez, R. L., Remich, S. A., and Hack., H. R., Wisniewski, M. L., Josleyn, M. D., et al. (2015) A recombinant vesicular stomatitis virus Ebola vaccine-preliminary report. N Engl. J. Med. 10.1056/NEJMoa1414216
21. Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., Johnson, A., Morton, J., Swope, K., Bohorov, O., Bohorova, N, et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53
22. Geisbert, T. W., Lee, A. C, Robbins, M., and Geisbert., J. B., Honko, A. N, Sood, V., Johnson, J. C, de Jong, S., Tavakoli, I., Judge, A., and Hensley., L. E., and Maclachlan, I. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of concept study. Lancet 375, 1896-1905
23. Warren, T. K., Wells, J., Panchal, R. G., and Stuthman., K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., Honnold, S., Bantia, S., Kotian, P., Chen, X., Taubenheim, B. R., et al. (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analog BCX4430. Nature 508, 402-405
24. Wolf, M. C, Freiberg, A. N, Zhang, T., Akyol-Ataman, Z., Grock, A., and Hong., P. W., Li, J., Watson, N F., Fang, A. Q., Aguilar, H. C, Porotto, M., Honko, A. N, Damoiseaux, R., Miller, J. P., Woodson, S. E., et al. (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 107, 3157-3162
25. Gehring, G., Rohrmann, K., Atenchong, N., Mittler, E., Becker, S., Dahlmann, F., Pöhlmann, S., Vondran, F. W., David, S., and Manns., M. P., Ciesek, S., and von Hahn, T. (2014) The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J. Antimicrob. Chemother. 69, 2123-2131
26. Wang, Y., Cui, R., Li, G., Gao, Q., Yuan, S., Altmeyer, R., and Zou, G. (2016) Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res. 125, 1-7
27. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875
28. Watt, A., Moukambi, F., Banadyga, L., Groseth, A., Callison, J., Herwig, A., Ebihara, H., Feldmann, H., and Hoenen, T. (2014) A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J. Virol. 88, 10511-10524
29. Pols, M. S., ten Brink, C., Gosavi, P., Oorschot, V., and Klumperman, J. (2013) The HOPS proteins hVps41 and hVps39 are required for homotypic and heterotypic late endosome fusion. Traffic 14, 219-232
30. Ebert, D. H., Deussing, J., Peters, C., and Dermody, T. S. (2002) Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J. Biol. Chem. 277, 24609-24617
31. Simmons, G., and Gosalia., D. N., Rennekamp, A. J., Reeves, J. D., and Diamond., S. L., and Bates, P. (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102, 11876-11881
32. Ryabchikova, E. I., and Kolesnikova., L. V., and Luchko, S. V. (1999) An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179, S199-S202
33. Geisbert, T.W., Young, H. A., and Jahrling., P. B., Davis, K. J., Larsen, T., Kagan, E., and Hensley, L. E. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus induced cytolysis of endothelial cells. Am. J. Pathol. 163, 2371-2382
34. Côté, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C. M., Hensley, L., Li, Q., Ory, D., Chandran, K., and Cunningham, J. (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344-348
35. Li, W., and Moore., M. J., Vasilieva, N., Sui, J., Wong, S. K., and Berne., M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., and Greenough., T. C., Choe, H., and Farzan, M. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454
36. Bröcker, C., Kuhlee, A., Gatsogiannis, C., Balderhaar, H. J., Hönscher, C., Engelbrecht-Vandré, S., Ungermann, C., and Raunser, S. (2012) Molecular architecture of the multisubunit homotypic fusion and vacuole protein sorting (HOPS) tethering complex. Proc. Natl. Acad. Sci. U.S.A. 109, 1991-1996
37. Seals, D. F., Eitzen, G., Margolis, N., Wickner, W. T., and Price, A. (2000) A Ypt/Rab effector complex containing the Sec1 homolog Vps33p is required for homotypic vacuole fusion. Proc. Natl. Acad. Sci. U.S.A. 97, 9402-9407
38. Shirato, K., Kawase, M., and Matsuyama, S. (2013) Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87, 12552-12561
39. Parenti, F., Beretta, G., Berti, M., and Arioli, V. (1978) Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. J. Antibiot. 31, 276-283
40. Borghi, A., Coronelli, C., Faniuolo, L., Allievi, G., Pallanza, R., and Gallo, G. G. (1984) Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin). J. Antibiot. 37, 615-620
41. Corti, A., Soffientini, A., and Cassani, G. (1985) Binding of the glycopeptide antibiotic teicoplanin to D-alanyl-D-alanine-agarose: the effect of micellar aggregates. J. Appl. Biochem. 7, 133-137
42. Corry, J., and Johnson., S. M., Cornwell, J., and Peeples, M. E. (2015) Preventing cleavage of the respiratory syncytial virus attachment protein in Vero cells rescues the infectivity ofprogeny virus for primary human airway cultures. J. Virol. 10.1128/JVI.02351-15
43. Balzarini, J., Pannecouque, C., De Clercq, E., Pavlov, A. Y., and Printsevskaya., S. S., Miroshnikova, O. V., Reznikova, M. I., and Preobrazhenskaya, M. N. (2003) Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J. Med. Chem. 46, 2755-2764
44. Preobrazhenskaya, M. N., and Olsufyeva, E. N. (2006) Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antiviral Res. 71, 227-236
45. Bereczki, I., Kicsák, M., Dobray, L., Borbás, A., Batta, G., Kéki, S., Nikodém, É. N., Ostorházi, E., Rozgonyi, F., Vanderlinden, E., Naesens, L., and Herczegh, P. (2014) Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies. Bioorg. Med. Chem. Lett. 24, 3251-3254
46. Maieron, A., and Kerschner, H. (2012) Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C. J. Antimicrob. Chemother. 67, 2537-2538
47. Obeid, S., and Printsevskaya., S. S., Olsufyeva, E. N., Dallmeier, K., Durantel, D., Zoulim, F., Preobrazhenskaya, M. N., Neyts, J., and Paeshuyse, J. (2011) Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J. Antimicrob. Chemother. 66, 1287-1294
48. De Burghgraeve, T., Kaptein, S. J., Ayala-Nunez, N. V., Mondotte, J. A., Pastorino, B., Printsevskaya, S. S., de Lamballerie, X., Jacobs, M., Preobrazhenskaya, M., Gamarnik, A. V., Smit, J. M., and Neyts, J. (2012) An analog of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS ONE 7, e37244
49. Balzarini, J., Keyaerts, E., Vijgen, L., Egberink, H., De Clercq, E., Van Ranst, M., Printsevskaya, S.S., Olsufyeva, E.N., Solovieva, S.E., and Preobrazhenskaya, M. N. (2006) Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 72, 20-33
50. Andrault, P. M., and Samsonov., S. A., Weber, G., Coquet, L., Nazmi, K., and Bolscher., J. G., Lalmanach, A. C., Jouenne, T., Brömme, D., Pisabarro, M. T., Lalmanach, G., and Lecaille, F. (2015) Antimicrobial peptide LL-37 is both a substrate of cathepsins S and K and a selective inhibitor of cathepsin L. Biochemistry 54, 2785-2798
51. Brogden, R. N., and Peters, D. H. (1994) Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47, 823-854
52. Cavalcanti, A. B., Goncalves, A.R., Almeida, C.S., Bugano, D. D., and Silva, E. (2010) Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst. Rev. 16, CD007022